Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Autoantibody-catalyzed hydrolysis of amyloid beta peptide.

Taguchi H, Planque S, Nishiyama Y, Symersky J, Boivin S, Szabo P, Friedland RP, Ramsland PA, Edmundson AB, Weksler ME, Paul S.

J Biol Chem. 2008 Feb 22;283(8):4714-22. Epub 2007 Dec 17.

2.

Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease.

Taguchi H, Planque S, Nishiyama Y, Szabo P, Weksler ME, Friedland RP, Paul S.

Autoimmun Rev. 2008 May;7(5):391-7. doi: 10.1016/j.autrev.2008.03.004. Epub 2008 Apr 9. Review.

3.

Immunological origin and functional properties of catalytic autoantibodies to amyloid beta peptide.

Paul S, Planque S, Nishiyama Y.

J Clin Immunol. 2010 May;30 Suppl 1:S43-9. doi: 10.1007/s10875-010-9414-5. Review.

4.

Reduced levels of IgM autoantibodies against N-truncated pyroglutamate Aβ in plasma of patients with Alzheimer's disease.

Marcello A, Wirths O, Schneider-Axmann T, Degerman-Gunnarsson M, Lannfelt L, Bayer TA.

Neurobiol Aging. 2011 Aug;32(8):1379-87. doi: 10.1016/j.neurobiolaging.2009.08.011. Epub 2009 Sep 24.

PMID:
19781815
5.

Beneficial catalytic immunity to abeta peptide.

Paul S, Planque S, Nishiyama Y.

Rejuvenation Res. 2010 Apr-Jun;13(2-3):179-87. doi: 10.1089/rej.2009.0958. Review.

6.

Amyloid-β oligomer specificity mediated by the IgM isotype--implications for a specific protective mechanism exerted by endogenous auto-antibodies.

Lindhagen-Persson M, Brännström K, Vestling M, Steinitz M, Olofsson A.

PLoS One. 2010 Nov 10;5(11):e13928. doi: 10.1371/journal.pone.0013928.

7.

Brain-reactive autoantibodies prevalent in human sera increase intraneuronal amyloid-β(1-42) deposition.

Nagele RG, Clifford PM, Siu G, Levin EC, Acharya NK, Han M, Kosciuk MC, Venkataraman V, Zavareh S, Zarrabi S, Kinsler K, Thaker NG, Nagele EP, Dash J, Wang HY, Levitas A.

J Alzheimers Dis. 2011;25(4):605-22. doi: 10.3233/JAD-2011-110098.

PMID:
21483091
8.
9.

Protease inhibitor coinfusion with amyloid beta-protein results in enhanced deposition and toxicity in rat brain.

Frautschy SA, Horn DL, Sigel JJ, Harris-White ME, Mendoza JJ, Yang F, Saido TC, Cole GM.

J Neurosci. 1998 Oct 15;18(20):8311-21.

10.

Increased Number of Plasma B Cells Producing Autoantibodies Against Aβ42 Protofibrils in Alzheimer's Disease.

Söllvander S, Ekholm-Pettersson F, Brundin RM, Westman G, Kilander L, Paulie S, Lannfelt L, Sehlin D.

J Alzheimers Dis. 2015;48(1):63-72. doi: 10.3233/JAD-150236.

11.

Specific amyloid β clearance by a catalytic antibody construct.

Planque SA, Nishiyama Y, Sonoda S, Lin Y, Taguchi H, Hara M, Kolodziej S, Mitsuda Y, Gonzalez V, Sait HB, Fukuchi K, Massey RJ, Friedland RP, O'Nuallain B, Sigurdsson EM, Paul S.

J Biol Chem. 2015 Apr 17;290(16):10229-41. doi: 10.1074/jbc.M115.641738. Epub 2015 Feb 27.

12.

Autoantibody activity in Waldenstrom's macroglobulinemia.

Stone MJ, Merlini G, Pascual V.

Clin Lymphoma. 2005 Mar;5(4):225-9. Review.

PMID:
15794853
13.

Recognition of IgG-derived peptides by a human IgM with an unusual combining site.

Yuriev E, Ramsland PA, Edmundson AB.

Scand J Immunol. 2002 Mar;55(3):242-55.

14.

Naturally occurring proteolytic antibodies: selective immunoglobulin M-catalyzed hydrolysis of HIV gp120.

Paul S, Karle S, Planque S, Taguchi H, Salas M, Nishiyama Y, Handy B, Hunter R, Edmundson A, Hanson C.

J Biol Chem. 2004 Sep 17;279(38):39611-9. Epub 2004 Jul 21.

15.

Circulating immune complexes of Abeta and IgM in plasma of patients with Alzheimer's disease.

Marcello A, Wirths O, Schneider-Axmann T, Degerman-Gunnarsson M, Lannfelt L, Bayer TA.

J Neural Transm (Vienna). 2009 Jul;116(7):913-20. doi: 10.1007/s00702-009-0224-y. Epub 2009 May 5.

16.

Value in development of a TAPIR-like mouse monoclonal antibody to Abeta.

Sambamurti K, Pappolla MA, Jagannatha Rao KS.

J Alzheimers Dis. 2008 Jun;14(2):175-7. No abstract available.

17.

Human monoclonal IgM with autoantibody activity against intermediate filaments.

Dellagi K, Brouet JC, Perreau J, Paulin D.

Proc Natl Acad Sci U S A. 1982 Jan;79(2):446-50.

18.

[Anti-smooth-muscle antibody activity of monoclonal IgM in Waldenström's disease].

Krulik M, Vittecoq D, Abuaf N, Genot JY, Homberg JC, Debray J.

Sem Hop. 1983 Jun 9;59(23):1737-41. French.

PMID:
6308799
19.

An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ.

Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, Lohmann S, Piorkowska K, Gafner V, Atwal JK, Maloney J, Chen M, Gogineni A, Weimer RM, Mortensen DL, Friesenhahn M, Ho C, Paul R, Pfeifer A, Muhs A, Watts RJ.

J Neurosci. 2012 Jul 11;32(28):9677-89. doi: 10.1523/JNEUROSCI.4742-11.2012.

20.

Autoimmune responses to amyloid structures of Abeta(25-35) peptide and human lysozyme in the serum of patients with progressive Alzheimer's disease.

Gruden MA, Davudova TB, Malisauskas M, Zamotin VV, Sewell RD, Voskresenskaya NI, Kostanyan IA, Sherstnev VV, Morozova-Roche LA.

Dement Geriatr Cogn Disord. 2004;18(2):165-71. Epub 2004 Jun 21.

PMID:
15211072

Supplemental Content

Support Center